A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer
Abstract
Loss of the phosphatase and tensin homolog (PTEN) tumor suppressor gene is a promising marker of aggressive prostate cancer. Active surveillance and watchful waiting are increasingly recommended to patients with small tumors felt to be low risk, highlighting the difficulties of Gleason scoring in this setting. There is an urgent need for predictive biomarkers that can be rapidly deployed to aid in clinical decision‐making. Our objectives were to assess the incidence and ability of PTEN alterations to predict aggressive disease in a multicenter study.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 04, 2015
- Source ID
- 10.1002/pros.23003
Entities
People
- Antonio Hurtado‐coll
- Daniel W Lin
- Dean A. Troyer
- Ian M. Thompson, Jr.
- James D Brooks
- Jeff Simko
- Jennifer Good
- Jeremy A. Squire
- Jesse K. Mckenney
- Ladan Fazli
- Lawrence D. True
- Martin Gleave
- Peter R. Carroll
- Peter S Nelson
- Raymond Lance
- Sarah Hawley
- Tamara Jamaspishvili
- Wei Wei
- Ziding Feng
Organizations
- Canary Foundation
- Cleveland Clinic
- Eastern Virginia Medical School
- Fred Hutchinson Cancer Center
- National Council for Scientific and Technological Development
- National Institutes of Health
- Queen's University
- Stanford University
- United States Department of Defense
- University of British Columbia
- University of California, San Francisco
- University of São Paulo
- University of Texas at Austin
- University of Washington